Most Read Articles
Audrey Abella, 20 Dec 2019
The combination of the immunomodulatory agent lenalidomide and the monoclonal antibody rituximab (R2) proved effective and safe in individuals ≥70 years with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL) compared with rituximab alone, according to a post hoc analysis of the phase III AUGMENT* trial presented at ASH 2019. 
27 Nov 2017
The amino sulphonic acid taurine may safely and effectively reduce portal pressure in cirrhotic patients, a study has shown.
26 Nov 2019
Podcast: Professor R. Scott Wright speaks about the potential role of inclisiran in providing durable reductions in LDL-cholesterol levels in patients with atherosclerotic cardiovascular disease.
Jairia Dela Cruz, 12 Dec 2019
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).

Infliximab, adalimumab show efficacy in psoriasis and IBD

09 Feb 2018

Infliximab and adalimumab are both effective for the treatment of psoriasis, psoriatic arthritis, ulcerative colitis and Crohn’s disease, while other biologics have shown efficacy for some, but not all, of these indications, according to the results of a systematic review.

To evaluate therapeutic options for patients with psoriasis and concurrent inflammatory bowel disease (IBD), a total of 2,282 articles were identified, of which 132 were selected. These clinical studies, published from 1 January 1947 to 14 February 2017, focused on biologic and systemic psoriasis medications in psoriasis, psoriatic arthritis, ulcerative colitis and Crohn’s disease.

The investigators selected randomized, controlled, double-blinded studies if available and, if not, the next highest level of available evidence.

Both infliximab and adalimumab had shown efficacy in psoriasis, psoriatic arthritis, ulcerative colitis and Crohn’s disease. Ustekinumab was effective against psoriasis, psoriatic arthritis and Crohn’s disease, while certolizumab had demonstrated efficacy in psoriatic arthritis and Crohn’s disease.

On the other hand, etanercept, secukinumab, brodalumab and ixekizumab were effective in psoriasis and psoriatic arthritis, but these medications could induce or worsen IBD. In addition, guselkumab was effective in psoriasis only.

This systematic review was limited by the absence of clinical trials involving treatment specifically for concurrent psoriasis and IBD.

“There is a significant association between psoriasis and IBD. Many treatments for psoriasis and psoriatic arthritis are also used for IBD,” according to the investigators.

In another systematic review, researchers found that biologic therapy was effective and safe for the treatment of hyperkeratotic palmoplantar psoriasis (PP). [Dermatol Ther (Heidelb) 2017;7:425-446]

“Adalimumab, guselkumab, ixekizumab, secukinumab and ustekinumab all showed >80-percent efficacy for the treatment of hyperkeratotic PP, while infliximab and ustekinumab showed moderate efficacy for the treatment of pustular PP, and infliximab was the most efficacious treatment for palmoplantar pustulosis,” they said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 20 Dec 2019
The combination of the immunomodulatory agent lenalidomide and the monoclonal antibody rituximab (R2) proved effective and safe in individuals ≥70 years with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL) compared with rituximab alone, according to a post hoc analysis of the phase III AUGMENT* trial presented at ASH 2019. 
27 Nov 2017
The amino sulphonic acid taurine may safely and effectively reduce portal pressure in cirrhotic patients, a study has shown.
26 Nov 2019
Podcast: Professor R. Scott Wright speaks about the potential role of inclisiran in providing durable reductions in LDL-cholesterol levels in patients with atherosclerotic cardiovascular disease.
Jairia Dela Cruz, 12 Dec 2019
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).